China Pharma Holdings (CPHI) Free Cash Flow Growth (3y) (2013 - 2026)
China Pharma Holdings (CPHI) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.68% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 39.19% |
| 10 | China Pharma Holdings | 629,344.02 | 460,870.02 | 285,487.00 | 66.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 66.04% |
| Dec 31, 2025 | -37.20% |
| Sep 30, 2025 | -92.27% |
| Jun 30, 2025 | 37.56% |
| Mar 31, 2025 | 46.88% |
| Dec 31, 2024 | 49.79% |
| Sep 30, 2024 | 64.82% |
| Jun 30, 2024 | -28.21% |
| Mar 31, 2024 | -28.32% |
| Dec 31, 2023 | -26.98% |
| Sep 30, 2023 | 57.98% |
| Jun 30, 2023 | 19.17% |
| Mar 31, 2023 | -33.62% |
| Dec 31, 2022 | 118.66% |
| Sep 30, 2022 | -27.47% |
| Jun 30, 2022 | -49.12% |
| Mar 31, 2022 | -41.59% |
| Dec 31, 2021 | -30.83% |
| Sep 30, 2021 | -43.99% |
| Jun 30, 2021 | 53.09% |